These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22754790)

  • 1. Inhibition of CXCLs/CXCR2 axis in the tumor microenvironment might be a potent therapeutics for pancreatic cancer.
    Ijichi H
    Oncoimmunology; 2012 Jul; 1(4):569-571. PubMed ID: 22754790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment.
    Sano M; Ijichi H; Takahashi R; Miyabayashi K; Fujiwara H; Yamada T; Kato H; Nakatsuka T; Tanaka Y; Tateishi K; Morishita Y; Moses HL; Isayama H; Koike K
    Oncogenesis; 2019 Jan; 8(2):8. PubMed ID: 30659170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.
    Ijichi H; Chytil A; Gorska AE; Aakre ME; Bierie B; Tada M; Mohri D; Miyabayashi K; Asaoka Y; Maeda S; Ikenoue T; Tateishi K; Wright CV; Koike K; Omata M; Moses HL
    J Clin Invest; 2011 Oct; 121(10):4106-17. PubMed ID: 21926469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases.
    Cheng Y; Ma XL; Wei YQ; Wei XW
    Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):289-312. PubMed ID: 30703432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation-Induced Innate Neutrophil Response in Tumor Is Mediated by the CXCLs/CXCR2 Axis.
    Zhang F; Mulvaney O; Salcedo E; Manna S; Zhu JZ; Wang T; Ahn C; Pop LM; Hannan R
    Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting both tumour-associated CXCR2
    Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
    Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic Tumor Microenvironment.
    Wang K; He H
    Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.
    Awaji M; Saxena S; Wu L; Prajapati DR; Purohit A; Varney ML; Kumar S; Rachagani S; Ly QP; Jain M; Batra SK; Singh RK
    FASEB J; 2020 Jul; 34(7):9405-9418. PubMed ID: 32453916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic significance of the CXCL1-CXCR2 axis in the tumor microenvironment of gastric carcinoma.
    Kasashima H; Yashiro M; Nakamae H; Masuda G; Kinoshita H; Morisaki T; Fukuoka T; Hasegawa T; Nakane T; Hino M; Hirakawa K; Ohira M
    PLoS One; 2017; 12(6):e0178635. PubMed ID: 28575019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCL2/CXCR2 axis induces cancer stem cell characteristics in CPT-11-resistant LoVo colon cancer cells via Gαi-2 and Gαq/11.
    Chen MC; Baskaran R; Lee NH; Hsu HH; Ho TJ; Tu CC; Lin YM; Viswanadha VP; Kuo WW; Huang CY
    J Cell Physiol; 2019 Jul; 234(7):11822-11834. PubMed ID: 30552676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of an in vitro 3D PDAC stroma rich spheroid model.
    Ware MJ; Keshishian V; Law JJ; Ho JC; Favela CA; Rees P; Smith B; Mohammad S; Hwang RF; Rajapakshe K; Coarfa C; Huang S; Edwards DP; Corr SJ; Godin B; Curley SA
    Biomaterials; 2016 Nov; 108():129-42. PubMed ID: 27627810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations.
    Ijichi H
    World J Clin Oncol; 2011 May; 2(5):195-202. PubMed ID: 21611096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target.
    Zhang W; Wang H; Sun M; Deng X; Wu X; Ma Y; Li M; Shuoa SM; You Q; Miao L
    Cancer Commun (Lond); 2020 Mar; 40(2-3):69-80. PubMed ID: 32237072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functions of the CXC ligand family in the pancreatic tumor microenvironment.
    Lee NH; Nikfarjam M; He H
    Pancreatology; 2018 Oct; 18(7):705-716. PubMed ID: 30078614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic cancer: Stroma and its current and emerging targeted therapies.
    Kota J; Hancock J; Kwon J; Korc M
    Cancer Lett; 2017 Apr; 391():38-49. PubMed ID: 28093284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic Stellate Cells: The Key Orchestrator of The Pancreatic Tumor Microenvironment.
    Thomas D; Radhakrishnan P
    Adv Exp Med Biol; 2020; 1234():57-70. PubMed ID: 32040855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises.
    Mei L; Du W; Ma WW
    J Gastrointest Oncol; 2016 Jun; 7(3):487-94. PubMed ID: 27284483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions.
    Jiang Z; Zhou C; Cheng L; Yan B; Chen K; Chen X; Zong L; Lei J; Duan W; Xu Q; Li X; Wang Z; Ma Q; Ma J
    J Exp Clin Cancer Res; 2018 Mar; 37(1):69. PubMed ID: 29587800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance.
    Erkan M; Reiser-Erkan C; Michalski CW; Kong B; Esposito I; Friess H; Kleeff J
    Curr Mol Med; 2012 Mar; 12(3):288-303. PubMed ID: 22272725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.